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Abstract Glucose-derived pyruvate is a principal source
of acetyl-CoA in all brain cells, through pyruvate dehyd-
ogenase complex (PDHC) reaction. Cholinergic neurons
like neurons of other transmitter systems and glial cells,
utilize acetyl-CoA for energy production in mitochondria
and diverse synthetic pathways in their extramitochondrial
compartments. However, cholinergic neurons require
additional amounts of acetyl-CoA for acetylcholine syn-
thesis in their cytoplasmic compartment to maintain their
transmitter functions. Characteristic feature of several
neurodegenerating diseases including Alzheimer’s disease
and thiamine diphosphate deficiency encephalopathy is the
decrease of PDHC activity correlating with cholinergic
deficits and losses of cognitive functions. Such conditions
generate acetyl-CoA deficits that are deeper in cholinergic
neurons than in noncholinergic neuronal and glial cells, due
to its additional consumption in the transmitter synthesis.
Therefore, any neuropathologic conditions are likely to be
more harmful for the cholinergic neurons than for non-
cholinergic ones. For this reason attempts preserving
proper supply of acetyl-CoA in the diseased brain, should
attenuate high susceptibility of cholinergic neurons to
diverse neurodegenerative conditions. This review
describes how common neurodegenerative signals could
induce deficts in cholinergic neurotransmission through
suppression of acetyl-CoA metabolism in the cholinergic
neurons.
Keywords Acetyl-CoA  Alzheimer’s disease 
Cholinergic neurons  Neurotoxins  Pyruvate
dehydrogenase  Thiamine deficiency
General Outline of Brain Energy Metabolism
Brain constitutes for 2 % of human body mass but under
resting conditions it utilizes 20 % of whole body oxygen
and glucose. Glucose is transported across the blood brain
barrier through insulin independent, low-affinity high-
capacity, glucose down regulated Glut 1 transporter. Due to
the high rate of glucose utilization by brain cells its con-
centration in CSF is equal to two/third of its level in gen-
eral circulation. Glucose is an almost exclusive energy
substrate in the brain that through glycolytic pathway
yields pyruvate, a key precursor of acetyl-CoA, which
feeds TCA cycle. The latter is synthesized almost exclu-
sively by pyruvate dehydrogenase complex (pyruvate:
lipoate oxidoreductase acceptor acetylating, PDHC) that
activities in whole brain, as well as in isolated brain
mitochondria are 4–10 times higher than in respective
fractions of non excitable tissues. The highest activity of
PDHC was found in the hippocampus and the lowest one
(60 % lower) in the medulla oblongata [1, 2]. These PDHC
patterns did not correlate with differential regional distri-
bution of ChAT activities [2, 3]. It might result form the
fact that cholinergic neurons form small about 1 % frac-
tions of entire brain cell population. Therefore, particular
interactions between energy and cholinergic metabolism
ought to be investigated using models containing greater
density of cholinergic neurons.
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Neurons that constitute about 10 %, of brain cells con-
sume 70 % of glucose and oxygen supplied to this organ.
That is due to the fact that neurons, possess high density/
high glucose affinity Glut 3 transporters and their in situ,
rates of metabolic fluxes of high-energy intermediates that
are at least 20 times faster than in glial cells (Fig. 1) [4].
Brain may also utilize acetoaetate/b-hydroxybytyrate as a
complementary source of acetyl-CoA [5, 6]. In physio-
logical conditions levels of these ketoacids in extracellular
fluids are well below 0.05 mmol/L. However, under path-
ologic conditions, such as diabetes, their extracellular
concentrations may reach levels as high as 5 mmol/L. At
such concentrations, ketoacids enter the brain through
MCTs competing effectively with lactate (Fig. 1). Under
in vitro conditions, these ketoacids were capable
maintaining normal levels of ATP and phosphocreatine in
different brain preparations. Moreover, in diabetic-ketotic
rat brain ketoacids along with glucose or pyruvate caused
marked rises acetyl-CoA, ACh synthesis and release from
isolated nerve terminals [7].
Under in vitro conditions, neuronal cells utilize lactate/
pyruvate as preferred energy substrates. The increase of
lactate in circulation during exercise or pathologic hypoxia
may cause several fold increase of its transport through the
BBB. Inside the cells lactate remains in equilibrium with
pyruvate due to very high activity of lactic dehydrogenase.
Therefore, the net rate of its flux to pyruvate depends on
utilization rate of the latter in PDHC and pyruvate car-
boxylase reactions. Pyruvate through PDHC reaction is
almost exclusive source of acetyl-CoA in neurons and
Fig. 1 Pathways of acetyl-CoA and energy metabolism in choliner-
gic neurons of neurodegenerating brain. Combination of diverse
neurotoxic signals contributes to Alzheimer’s and other types of
cholinergic encephalopathies. They inhibit PDHC and acetyl-CoA
synthesis yielding energy deficits of entire population of brain cells.
However, cholinergic neurons are more susceptible than others to
these neurodegenerative inputs. Cytotoxic-signal induced excessive
depolarization of glutaminergic terminals causes increase of [Zn] and
[Glu] in the synaptic cleft. Zn, Ca, and chronically accumulated Al
enter depolarized postsynaptic cholinergic neurons through ZnTs,
VGCC, NMDA and/or Ab high permeability channels. The increase
of cytoplasmic [Ca2?] activates nNOS, whereas subsequent everload
of mitochondria with this cation inhibits PDHC. Also Zn or NO-
derived peroxynitrite radicals acutely inhibit PDHC and other other
enzymes of TCA cycle yielding depression of acetyl-CoA synthesis
and its utilization for ATP production in the mitochondria. Chronic
accumulation of Ab in extra and intracellular compartments, alone or
in combination with Ca and other metals alters multiple transport
entities in the plasma and mitochondrial membranes and directly
inhibits PDHC and aconitase. The prolonged depolarization and
energy deficts increase nonquantal ACh release and inhibit its quantal
Ca-dependent release. These conditions limit direct or ACL-depen-
dent transport acetyl-CoA from mitochondria to the site of ACh
synthesis in the synaptoplasmic compartment. The decrease of acetyl-
CoA in the synaptoplasm causes instant inhibition of ChAT, yielding
depression of ACh pool and rates of its quantal release. Prolonged
decrease of cytoplamic [acetyl-CoA] results in adaptative suppression
of ChAT expression aggravating deficits of cholinergic neurotrans-
mission. Part of acetyl-CoA pool is utilized for intramitochondrial
NAA synthesis, which is subsequently released out of the neuron.
Decrease of mitochondrial acetyl-CoA results in energy deficits, and
correlates with death rate of cholinergic neurons. Red arrows
activation, blue arrows inhibition, green letters enzymes, black boxes
neurotoxic agents (Color figure online)
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other types of brain cells (Fig. 1). However, anaplerotic
reaction of pyruvate carboxylation to oxaloacetate by
pyruvate carboxylase occurs mainly in astrocytes [8].
Therefore, oxaloacetate has to be transported into the
neurons through indirect oxaloacetate-aspartate and gluta-
mine-glutamate shunts. Both metabolites are required by
citrate synthase to feed TCA cycle.
Also astrocytes produce large amounts of lactate. Frac-
tion of this metabolite is taken up and utilized by the
neurons thanks to high expression of MCT in the neuronal
plasma membranes, and PDHC activity in their mito-
chondria [9]. Therefore, the astrocyte-derived lactate is
postulated to be an important precursor of acetyl-CoA and
oxaloacetate-substrates for condensation reaction and
energy production in neurons. Results of in vitro experi-
ments on brain slices, synaptosomes and cultured neuronal
cells demonstrate that lactate/pyruvate with L-malate are
better energy substrates and precursors of acetyl moiety for
ACh synthesis than glucose [10].
On the contrary, under in vivo conditions blood lactate,
even in high concentrations, could not fully replace the
glucose, despite of robust expression of MCT on the blood
brain barrier. Only during the suckling period brain is
capable to extract lactate from circulation [11]. The source
of discrepancies between in vivo and in vitro experiments
remains unknown.
Fig. 2 Selected correlations
between different parameters of
energy and ACh metabolism in
differentiated SN56 cholinergic
neuronal cells and brain nerve
terminals under various
neurotoxic and neuroprotective
conditions (a–d): a significant
correlation between cell
viability and PDHC activity;
b significant correlation
between cell viability and
acetyl-CoA level in their
mitochondria; c significant
correlation between cytoplasmic




acetyl-CoA level; e significant
correlation between PDHC and
ChAT activities in differentiated
cholinergic cells and lack of
such correlation in
nondifferentiated ones;
f significant inverse correlations
between ChAT activities
(circles)/ACh contents
(triangles) and whole cell
acetyl-CoA levels in different
genetically and
postranslationally modified
phenotypes of cholinergic SN56
cells. (1) Native differentiated
(DC) and nondifferentiated
(NC) SN56 cells; (2) TrkA
expressing T17 NC/DC SN56
cells; 3. 2ChAT overexpressing
NC/DC SN56 cells. Data
recalculated from: [27, 35–38,
45, 54–56, 79, 131]
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Neurons have no capacity for acetate utilization. How-
ever, they synthesize large amounts of N-acetyl-N-aspartate
(NAA) in aspartate-CoA transferase (acetyl-CoA:L-aspar-
tate N-acetyltransferase, EC 2.3.1.17) reaction located in
their mitochondria. Neurons contain 98.7 % fraction of
overall brain pool of this metabolite (Fig. 1). Its intraneu-
ronal concentration reaches levels 20 mmol/L [12]. NAA is
transported to oligodendrocytes, where it may be hydro-
lysed to acetate by aspartoylacylase (aminohydrolase II,
EC 3.5.1.15) and converted back to acetyl-CoA by acetyl-
CoA synthetase (acetate:CoA ligase AMP, EC 6.2.1.1).
Overall NNA concentration in the brain is in the range
of 10 mmol/kg. Therefore, its signal in the brain can be
easily detected by PET and used as marker of viability of
brain neurons. The levels of NAA were found to be
decreased in the specific regions of cerebral cortex in
various brain pathologies including: Alzheimer’s, Parkin-
son’s diseases as well as Wernicke, dialysis and aluminum
encephalopathies [12]. In each of these pathologies the
PDHC activity and parameters of energy metabolism were
found to be decreased. Experiments on animal and cellular
models of these encephalopathies demonstrated inhibition
of PDHC that correlated with suppression of acetyl-CoA
levels in the mitochondrial compartment and the rate of
cell death (Figs. 1, 2) [1, 6, 13–15]. It might directly
decrease the rate of NAA synthesis in the aspartate ace-
tyltransferase reaction. However, no direct correlation
studies are available.
Oral administration of large doses of glyceride triacetate
was reported to cause marked increases of acetyl-CoA and
phosphocreatine levels in the rat brain [16]. This rise was
linked with attenuation LPS-induced inflammatory reac-
tions in microglia and improvement of energy metabolism
in glial cells [16, 17].
Total number of astrocytic, microglial and oligoden-
droglial cells in the brain is 10 times greater than that of the
neurons, but their oxidative metabolism utilizes only 30 %
of the brain glucose. They display about 4 times lower
activities of PDHC, ketoglutarate dehydrogenase (2-oxo-
glutarate:lipoate oxidoreductase acceptor acylating, EC
1.2.4.2., KDHC) and other enzymes of oxidative metabo-
lism than neurons [18, 19]. High level of phosphorylation
of E1 subunit of PDHC in astrocytes, could also inhibit
pyruvate consumption in this compartment [20]. On the
contrary, in astrocytes rates of glucose and lactate uptake
are 2–4 times faster than in isolated neurons. Therefore,
astrocytes may release both lactate and glucose to support
neuronal energy metabolism [21, 22]. Accordingly, oxi-
dative metabolism in neurons, but not in astroglia, was
strongly activated by pyruvate and lactate. It gives rise to
the hypothesis that under hypoxic/hypoglycemic conditions
lactate may replace glucose as a principal energy substrate
[21, 23].
Astrocytes also avidly take up glutamate, released from
glutamatergic terminals, through EAAT1-2 transporters
and convert it to L-glutamine in Pi-activated glutamine
synthetase reaction [24]. Thereby, they protect postsynap-
tic neurons against excitotoxic injury, by excess of extra-
cellular L-glutamate. In addition, astrocytes contain high
activities of pyruvate carboxylase yielding production large
amounts of oxaloacetate [8]. They supply these metabolites
to the neurons in form of glutamine and aspartate, through
glutamine-glutamate and aspartate shuttles, respectively
[8]. Most of compartmentalization studies were performed
on isolated primary neuronal or glial cell cultures, to deal
with possibly homogenous cellular populations [24]. One
should, however keep in mind that these cultures are still
heterogeneous. For instance, primary neuronal cultures
consist of neurons of different transmitter systems with
dominating fraction of glutamatergic ones.
However, activities of PDHC in different brain regions
displayed no correlations with distribution specific markers
of cholinergic pericarya and/or terminals [2, 3, 25]. Also,
differentiation of SN56 cholinergic cells was accompanied
by the decrease but not increase of PDHC activity [26, 27].
It indicates that rate of acetyl-CoA synthesis by PDHC in
cholinergic neurons is not positively linked with expression
their transmitter phenotype (Fig. 1). On the other hand,
during postnatal development the increase of ChAT
activity in cerebrum was accompanied by respective ele-
vations in PDHC levels, what might be compatible with
maturation-induced activation all transmitter systems [3,
28, 29].
Age Dependent Modifications
Brain maturation stimulates glucose uptake, glycolysis and
oxidative pathways due to increased expression of
respective genes and enzyme levels. These alterations
display temporal correlations with maturation-dependent
elevations in brain cholinergic and glutamatergic trans-
mitter metabolism, both requiring an adequate provision of
acetyl-CoA by PDHC and its flux through TCA [28, 30,
31]. On the other hand, physiologic brain aging is char-
acterized by continuous, although relatively small, decline
of structural and metabolic markers of cholinergic neurons
and their key physiological neurotransmitter functions.
Also, no alterations in activities of key enzymes of oxi-
dative metabolism including PDHC, KDHC, aconitase and
other enzymes of TCA cycle and respiratory chain were
found [25]. However, in these conditions deficits in several
antioxidative species such as glutathione, carnitine and
lipoate along with excessive glutamatergic signaling, and
free radical production appeared [32–34]. That, made aged
brains increasingly vulnerable to common pathologic
conditions such as hypoxia, hypoglycemia, excitotoxic
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stimulation, amyloid-b accumulation, Zn, Fe, Al excess
and thiamine (TD) or other vitamin deficiences (Fig. 1).
All these pathologic signals strongly inhibited PDHC,
KDHC, aconitase [citrate (isocitrate)hydrolase, EC
4.2.1.3.] and other key enzymes of acetyl-CoA and energy
metabolism (Fig. 1) [14, 27, 35–38]. It might cause fast
decay of cholinergic neurons located in the septal nuclei
(Fig. 2a, b), thereby aggravating age-dependent physio-
logic limitations of memory and cognitive functions [39].
In addition, other studies on 24 months rats revealed
marked 40 % decrease of PDHC activity, with concomitant
increases in expression and activity of pyruvate dehydro-
genase kinase (ATP:[pyruvate dehydrogenase (acetyl-
transferring)] phosphotransferase, EC 2.7.11.2.), yielding
hiperphosphorylation of PDHC-E1 subunit. That, could be
responsible for decreased levels of ATP and increased
accumulation of lactate in senescent brains [40].
Key Role of Acetyl-CoA
Acetyl-CoA is a key energy precursor-intermediate in all
cells of our organism. In the brain it is almost exclusively
synthesized in the mitochondria in PDHC reaction pro-
viding 97 % of energy (Fig. 1). Brain does not utilize fatty
acids as a source of acetyl-CoA. However, during systemic
ketosis it may utilize b-hydroxybutyrate-derived acetoac-
etate through acetoacetyl-CoA synthestase, succinyl-CoA
acyltransferase, and acetoacetyl-CoA thiolase reactions.
Irrespective of the origin, acetyl-CoA is efficiently incor-
porated into TCA cycle through high activity citrate syn-
thase step. Its equilibrium constants equal to 2.2 9 108
shifts this reaction far toward citrate formation [41]. It
causes the level of acetyl-CoA in brain mitochondria being
low and strongly dependent on the rate of its synthesis by
PDHC (Fig. 1). Therefore, any conditions suppressing
PDHC activity decrease acetyl-CoA level in the brain
mitochondria. Significant correlations between PDHC
activity and acetyl-CoA levels have been reported in our
studies on different models of neurodegeneration (Fig. 2a,
b) [6, 12, 42–44].
In last 40 years number of studies directly assessed
acetyl-CoA content in different brain preparations [7, 43,
45–55]. However, majority of them did not take into
account apparent differences in acetyl-CoA distribution
between mitochondrial and cytoplasmic compartments in
cholinergic and noncholinergic neurons as well as in glial
cells. Only experiments performed either on brain nerve
terminals or in clonal cholinergic neuronal SN56 cell lines
assessed subcellular distribution of acetyl-CoA, so far [14,
36, 38, 45, 56]. These models enabled one to investigate
acetyl-CoA shifts between mitochondrial and cytoplasmic
compartment in pure cholinergic cells under different
physiologic and pathogenic conditions (Figs. 1, 2).
Small fraction of mitochondrial acetyl-CoA, not used in
TCA cycle, serves as a source of acetyl units for different
synthetic processes taking place in cytoplasmic compart-
ment of these neuronal cells (Fig. 1). However, in resting
neurons inner mitochondrial membrane is relatively
impermeable for acetyl-CoA and other acyl-CoA esters
[6, 57]. Therefore, acetyl units are transported to cytoplasm
indirectly, in the form of citrate, acetyl-L-carnitine, or
acetate (Fig. 1) [57]. Citrate leaves mitochondria through
dicarboxylate transporter to be cleaved by ATP-
citrate lyase (acetyl-CoA:oxaloacetate C-acetyltransferase
[(pro-S)carboxymethyl-forming, ADP phosphorylating, EC
2.3.3.8, ACL) to acetyl-CoA and oxaloacetate. Studies with
specific inhibitor of ACL (-) hydroxycitrate revealed that
this pathway provides about 30–50 % of acetyl units in the
cytoplasmic compartment of both neuronal and glial cells
[44, 45, 58]. On the other hand, carnitine acetyl transferase
system (acetyl-CoA:carnitine O-acetyltransferase, EC
2.3.1.7) in the brain mitochondria was found to be active
only in the presence of excess of exogenous acetyl-L-car-
nitine (ALC) [59, 60]. Also immature brains were reported
to take up and metabolize ALC from the blood more avidly
than the adult ones [61].
Studies on whole brain mitochondria of mixed glial-
neuronal origin have demonstrated that pathophysiologi-
cally relevant [Ca2?] of 10-6 mol/L concentrations, evoked
direct release of acetyl-CoA (Fig. 1) [14, 45, 50]. Also in
synaptosomes adequate fraction of their mitochondrial
acetyl-CoA was found to reach cytoplasm directly through
Ca-activated, verapamil-inhibited pathway (Fig. 1) [45,
56]. In primary neurons depolarization increased cyto-
plasmic [Ca2?], and opened reversible, high permeability
transition anionic channels (PTP) through which acetyl-
CoA moieties might diffuse from mitochondria to cyto-
plasm, down the concentration gradient [36, 62].
In addition, acetyl-CoA may leave mitochondria as
NAA. [12]. Concentrations of substrates for aspartate
N-acetyltransferase, aspartate and acetyl-CoA, are esti-
mated to be about 1.0 and 0.12 mmol/L [36], whereas
corresponding Km values are equal to 0.58 and
0.058 mmol/L, respectively [36, 63]. Therefore, patholo-
gies that depress acetyl-CoA formation by PDHC in the
brain are likely to decrease its NAA levels. Indeed, the
loss of NAA was observed in brain PET scans of AD and
PD patients [13, 64]. Neurons cannot utilize NAA as a
source of acetate as they contain no aspartoylhydrolase in
their cytoplasm. Therefore, NAA may serve as an acetyl
moiety donor after its release to extracellular space fol-
lowed by its uptake by oligodendroglia. The metabolic
flux of acetyl units through this pathway was estimated to
be equal to 2.5–3.0 % of rates of glucose to pyruvate and
1.2 % pyruvate to acetyl-CoA conversion rates, respec-
tively [12, 36].
Neurochem Res (2013) 38:1523–1542 1527
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These data indicate that there is an intra and intercellular
compartmentalization of acetyl-CoA in the brain. Acetyl-
CoA in each cellular compartment of the brain forms two
metabolically linked but functionally independent pools
(Fig. 1). Brain mitochondria are the primary compartment
for acetyl-CoA synthesis by the PDHC. Over 90 % of
acetyl-CoA is subsequently utilized for energy production.
Thus, availability of this metabolite in mitochondria may
be a key factor determining viability of neuronal and other
cell types in brain (Figs. 1, 2b) [27]. Concentration of
acetyl-CoA in the mitochondrial matrix is 5–7 times higher
than in cytoplasm and might determine rates of its transport
to latter compartment [36]. On the other hand, the influence
of cytoplasmic acetyl-CoA itself on velocity of different
synthetic pathways seems to be independent of the mito-
chondrial pool (Fig. 2e) [38, 65].
Age-Dependent Alterations of Brain Acetylcholine
Metabolism
Cholinergic Transmission
The cholinergic transmission is performed by specific
groups of neurons, which synthesize ACh in cytoplasmic
compartment, accumulate in synaptic vesicles and release
it into the synaptic cleft in a quantal, Ca-dependent mode.
Neurotransmitter binding with subsequent activation of
postsynaptic muscarinic and nicotinic receptors is con-
nected with cognitive functions, emotional reactions as
well as short and long term memory formation in humans
and animals.
ACh is synthesized by choline acetyltransferase (acetyl-
CoA:choline O-acetyltransferase, EC 2.3.1.6., ChAT) from
acetyl-CoA and choline in cytoplasmic compartment of
cholinergic neuron axonal terminals which equilibrium
constant equal to 13 favors formation of this transmitter:
choline þ acetyl-CoAACh þ CoA ð1Þ
The release of ACh creates out of equilibrium conditions
in transmitter synthesizing compartment and triggers
ChAT reaction. There is thought, that transmitter
functions are executed by ACh synthesized in cholinergic
nerve terminals and accumulated in synaptic vesicles and
released in a quantal mode in response to their
depolarization. The content of ACh in cholinergic
neurons is maintained on quite stable level despite of
marked variations in their activity [6, 66]. It indicates that
ChAT activity in cholinergic neurons in situ is high enough
to prevent ACh depletion during their activity. Levels of
acetyl-CoA and choline in cytoplasm of cholinergic
neurons were found to be much below their optimal
concentrations used in assay media [6, 66]. Therefore, the
rate of ACh synthesis under out of equilibrium conditions,
induced by the evoked transmitter release, may be
regulated by both ChAT protein level, as well as by
substrates availability.
Both ChAT and VAChT are recognized specific struc-
tural markers for cholinergic neurons. Their levels depend
on the expression of CHAT and VACHT genes sharing
common cholinergic locus regulated by promoters, acti-
vated by CREB and retinoic acid receptors (RAR) [67].
Also nerve growth factor (NGF) was found to induce dif-
ferentiation of septal cholinergic neurons through multiple
signaling pathways linked with TrkA, high affinity surface
receptors and suppressed through low specificity p75
receptors [27, 54, 55, 68]. Activation of these pathways
leads to increased expression of ChAT, VAChT, high
affinity choline transport system (CHT1) yielding mor-
phologic maturation and activation of ACh metabolism
[54, 69, 70].
Both in ageing animals and in humans decrease in
cortical ACh metabolism precedes those in ChAT and
VAChT expression [6, 71–73]. In rats, loses in these cho-
linergic markers, as well as decreased density of cholin-
ergic neurons in the septum, and progressive cognitive
deficits appeared several months later. However, in
senescence-accelerated, 8th and 12th month old mice, loses
in activity and mRNA for ChAT in hippocampus and
cerebral cortex as well as decreases in density of septal
cholinergic neurons significantly correlated with deterio-
ration their spatial cognitive tests [74]. There are sugges-
tions that age-linked neurodegeneration may be caused by
disequilibrium between TrkA and p75NTR receptors [75].
Metabolism of Acetyl Moiety of Acetylcholine
There is little data on regulation of acetyl-CoA metabo-
lism in brain cholinergic neurons. It results from the fact
that cholinergic neurons constitute about 1 and 10 % of
whole brain cell and nerve terminal populations, respec-
tively [76]. Therefore, any conclusion concerning patho-
logic alterations in acetyl-CoA metabolism in cholinergic
neurons, are drawn with assumption, that changes of this
metabolite in cholinergic and noncholinergic compart-
ments remain the same. However, that may not be the
case. For instance, clonal SN56 cholinergic cells from
mice septum, with low and high expression of the cho-
linergic phenotype, had higher and lower levels of acetyl-
CoA in their mitochondria, respectively (Fig. 2f) (Table 1)
[38, 54, 77].
Acetyl-CoA for synthesis of transmitter pool of ACh is
synthesized almost exclusively inside of cholinergic neu-
ron mitochondria by PDHC from glucose-derived pyruvate
(Fig. 1). In ketotic diabetes part acetyl units for ACh
synthesis may be provided by acetoacetate/b-
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hydroxybutyrate [5, 7]. It is estimated, that only 1–3 % of
acetyl-CoA pool synthesized in cholinergic neurons is
utilized for ACh production. Despite of that there is a tight
interdependence between pyruvate oxidation and ACh
content and rate of release both in whole brain, isolated
synaptosomes as well as in cultured cells [15, 35, 78, 79].
That may be due to the competition for acetyl-CoA
between high velocity TCA and relatively slow rate
transporting pathways (Fig. 1) (Table 1).
Among several pathways of acetyl group transfer
through the mitochondrial membrane (see ‘‘Key Role of
Acetyl-CoA’’) only two seem to be significant sources of
acetyl-CoA for ACh synthesis in the cholinergic neurons.
They are: ACL pathway, providing 20–50 % of acetyl
units, and the direct efflux of acetyl-CoA through Ca-
dependent reversible PTP (Fig. 1) [44, 45, 50].
In addition, ACL pathway provides acetyl-CoA for
acetylation of histones and different structural proteins of
various mammalian cells including neurons [65]. Thereby,
acetyl-CoA-dependent disturbances in protein acetylation
may contribute to epigenetic pathomechanisms of Alzhei-
mer’s and other neurodegenerative diseases [80, 81].
During postnatal development of cerebrum activity of
ChAT increased several-fold, but the ACL activity
remained on stably high level. On the other hand, in cer-
ebellum containing no cholinergic elements, activity of
ACL was decreased by about 70 % [3, 31]. Significant
correlations have been found between ChAT and ACL
activities in different regions of the brain, and in lesioned
hippocampus [82]. Also, differentiation of cholinergic S-20
but not NIE-115 dopaminergic neuronal cells caused two-
fold increase of ACL activity [83].
There is generally accepted that in resting cells in situ,
mitochondrial inner membrane is impermeable to acetyl-
CoA [45, 57]. However, depolarization-induced increase of
cytoplasmic Ca2? may generate reversible PTP, allowing
transient direct release of acetyl-CoA from mitochondria
to cytoplasm [45, 62, 84]. Studies with Ca chelators and
Ca-channel antagonists indicate that up to 60–70 % of
acetyl-CoA for ACh synthesis is transported out of mito-
chondria by the direct release [56].
ALC is thought to be another alternative source of acetyl
units for brain ACh synthesis. Under in vivo conditions
systemic application of ALC was found to improve energy
and ACh metabolism in the brain, as well as cognitive
performance of aged or pharmacologically depressed ani-
mals [60, 85, 86]. In fact, dietary supplementation of mice
with ALC attenuated pentylenetetrazole-induced seizures
through restoration normal levels of ATP and NAA [87].
Beneficial effects of ALC supplementation might result
from general improvement of energy metabolism and
synthesis of structural lipids but not from specific influence
on neurotransmission in cholinergic neurons [86, 88].
However, none of these reports assessed acetyl-CoA con-
tent in ALC treated brains. In turn, our data demonstrate
that addition of ALC to cultured cholinergic neuroblastoma
cells increased acetyl-CoA level in their cytoplasm and
prevented A-b induced suppression of ACh metabolism
(Fig. 2c, d) [55].
Direct interactions between acetyl-CoA and ACh
metabolism were demonstrated by studies on nondiffer-
entiad and cAMP/retinoic acid or NGF-differentiated
cholinergic SN56 neuroblastoma cells (Fig. 2c, d). They
revealed that differentiation-evoked elevations in their
ChAT and ACh were accompanied by suppression of
acetyl-CoA level in their mitochondria and its increase in
the cytoplasmic compartment (Fig. 2f) [54, 55].
Early and Late Mechanisms of Energy and Acetyl-CoA-
Dependent Disturbances in Cholinergic
Encephalopathies
Principal clinical symptoms of AD and other cholinergic
encephalopathies include progressive cognitive deficits
leading to dementias, frequently combining with motor
disability [89–91]. They correlate well with the degree of
functional and structural loses of basal forebrain choliner-
gic neurons projecting axons to hippocampus and different
cortical areas [92]. Another key feature of these patholo-
gies is the suppression of energy metabolism, which cor-
relates with losses of cholinergic markers in affected areas
of brain cortex or spinal cord segments. Dysfunction of
brain mitochondria is thought to be both the consequence
of pathologic insults as well as a source of signals trig-
gering neurodegeneration [93–95]. There is a hypothesis,
that particular susceptibility of cholinergic neurons to
degeneration results from the fact that their acetyl-CoA,
synthesized in mitochondria by PDHC is used not only for
energy production in TCA cycle and respiratory chain but
also for ACh synthesis in the cytoplasmic compartment
(Fig. 2a, b, f) [6, 27, 78, 96].
Alzheimer’s Disease
Alzheimer’s disease (AD) is the most frequent form of
dementia in senescent population. Estimated number of
patients suffering of this pathology reaches 25 million
worldwide [97]. AD is a clinical-phenotypic presentation
of various sporadic and inherited diseases. Immunohisto-
chemical examinations of autopsied brains reveal accu-
mulation of extracellular amyloid-b (Ab) deposits and
neurofibrillary tau protein type degeneration inside the
neurons. The amyloidogenic form is Ab1–42 containing 42
aminoacids, originates from proteolytic processing of
transmembrane amyloid precursor protein (APP), by the
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amyloid-b cleaving enzyme (BACE1, b-secretase). Domi-
nating product of APP proteolysis by ADAM (a-secreta-
ses) is 26 aminoacid non-amyloidogenic peptide P3
(Ab17–42 fragment) [98, 99].
The large fraction of sporadic AD patients is carrying
double copies of APOE4 alleles [100, 101]. Moreover,
these patients display significant associations with down-
regulation of multiple transcripts of genes involved in
oxidative phosphorylation, energy metabolism as well as
with synaptic vesicles docking and fusion [101–103]. AD
patients, being APOE4 carriers displayed strong correlation
between suppression of KDHC, PDHC and ChAT activities
in brain cortex and cognitive dysfunction rate [13, 104].
Reduced activities of PDHC and KDHC in autopsied AD
brains displayed strong inverse correlations with clinical
dementia rating [13, 105]. Also, glucose Glut 1 and 3
transporters density was reduced in affected brain areas, as
demonstrated by in vivo PET and in post mortem cyto-
chalasin B binding studies [106, 107].
The key biochemical and histopathologic finding in AD
brains is preferential loss of cholinergic neurons located in
septal nuclei, and their axonal projections to hippocampus
and several areas of brain cortex. The decreases of several
cholinergic markers such as ChAT, CHT1, VAChT activ-
ities and protein levels were observed post mortem in
affected brain areas [71, 92, 105, 108]. The loss of cho-
linergic markers correlated with both suppression of energy
metabolism and severity of dementia shown shortly before
patient’s death [13, 92, 108]. Neuronal loss has been con-
sistently shown in key cholinergic brain nuclei in sixty-
seven studies over 20 year period [108]. On the other hand,
several noncholinergic transmitter systems were not or
much less suppressed by these conditions [109, 110, 111].
Several putative pathomechanisms are involved in AD
encephalopathy. They include: Ab1–42 accumulation, ex-
citotoxicity/NO excess, mitochondrial dysfunction,
hypoxia/anoxia/hypoglycaemia, oxygen radicals formation,
inflammation, metals (Ca2?, Zn2?, Fe2?, Al3?) accumu-
lation, or neurothrophin depletion, which were investigated
as cytotoxic signals in AD (Fig. 2) [27, 90, 91, 93, 94, 112–
118]. Also activation of microglia yielding increased
release of proinflamatory interleukins may induce neuro-
degeneration through Wnt or p75 neurotrophin receptor-
dependent signal transduction pathways [75, 119, 120]. On
the other hand, anti-p75/Wnt antibodies or silencing
respective genes, protected against excitoxicity/inflamma-
tion-induced loss of cholinergic neurons [54, 121].
Most of these cytotoxic signals directly affected activi-
ties of enzymes linked with energy and acetyl-CoA
metabolism in humans as well as animal and cellular
models of AD [13, 27, 96, 102, 104, 118].
Therefore, the key effects of diverse neurodegenerative
signals were limitations in acetyl-CoA availability and its
intraneuronal distribution, yielding preferential disintegra-
tion of cholinergic neurons in AD brains (Figs. 1, 2). In fact,
suppression of PDHC and mitochondrial energy deficits
preceded appearance of AD pathology in the brains of
transgenic 3xTg-AD mice. However, microarray studies
revealed that in late-dementive phase of AD the depression
of oxidative phosphorylation was accompanied by up-reg-
ulation of those genes [96]. It suggests that down-regulation
of energy metabolism in the course of AD might be a pro-
tective response of surviving neurons to decreased supply of
glucose and oxygen taking place in this pathology [96].
Excitoxicity
Several common pathologies of ageing brain like general
or focal hypoxia, hypoglyceamia, inflammation, or thia-
mine deficits, cause depolarization and Ca-overload of
neuronal and non neuronal cells. Glutamatergic neurons
constitute 50 % of all brain neurons and synaptic terminals
[122]. Prolonged pathologic depolarization yields an
excessive co-release of glutamate and Zn from brain
‘‘gluzinergic’’ terminals, triggering action potentials
through NMDA, AMPA receptors and other voltage gated
Ca channels located on postsynaptic neurons including
cholinergic ones [123–125]. They cause dysfunction of
postsynaptic neurons that, when aggravated, may evolve
toward apoptosis or necrosis [126, 127].
Energy deficits also inhibit uptake of glutamate by
adjacent astrocytes, due to the down-regulation of EAA,
GLAST and GLT1 transporters and inhibition of their
glutamine synthetase [128]. It increases glutamate and Zn
levels within the synaptic clefts, yielding sustained depo-
larization of postsynaptic neurons, as well as adjacent as-
troglial and microglial cells [117]. The disruption of Ca2?
homeostasis affects enzymes linked with pathways
involved in energy, neurotransmitter, and NO metabolism,
which seem to be primary targets for excitotoxic signaling
in the brain [37, 38, 118]. The Ca2? excess in the mito-
chondrial compartment yields inhibition of PDHC due to
activation of PDH kinase, being at least in part, the cause of
acetyl-CoA deficits in subcellular compartments of cho-
linergic neuronal cells (Fig. 2) [27, 38, 129].
Zn Neurotoxicity
Zn co-released with glutamate from overexcited ‘‘gluzin-
ergic’’ terminals may reach high, up to 0.3 and 1.0 mmol/
L, concentrations in the synaptic cleft [113, 122]. Subse-
quently Zn is avidly taken up from the synaptic cleft by
depolarized postsynaptic glial and neuronal cells including
cholinergic ones, through the voltage gated, dilthiazem-
sensitive Ca-channels and specific Zn-transporting proteins
[38, 116, 130]. Extended depolarization brings about
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overloading of postsynaptic neurons with Zn, irrespective
of expression of their cholinergic phenotype. Zn accumu-
lated in postsynaptic cholinergic neurons was found to
inhibit several enzymes of energy metabolism with
pathophysiologically relevant potencies including:
KDHC [ NADP isocitrate dehydrogenase [ aconi-
tase [ PDHC [37, 38]. The inhibitory interactions of Zn
with lipoate binding sites of PDHC and KDHC could be
reversed by the delayed application of lipoamide or che-
lating agents. On the contrary, inhibition of aconitase and
isocitrate dehydrogenase appeared to be irreversible [37].
Such inhibitory pattern may impede therapeutic attempts
aimed to rescue energy metabolism in excitotoxicity-
affected brains. Moreover, in human AD brain cortex the
alternation pattern of enzymes of energy metabolism
appeared to be very similar to that found in Zn-treated
SN56 cholinergic cells [13, 37]. It provides a circumstan-
tial evidence on significance of aberrations in intraneronal
distribution of Zn for the pathomechanism of AD.
The Zn-evoked inhibition of PDHC and other enzymes
listed above, explains suppression of mitochondrial acetyl-
CoA levels, and inhibition its metabolic flux through TCA
cycle as a cause of ATP depletion and neuronal loss
resulting from excitotoxic insults (Table 1; Fig. 2) [37, 38,
125, 126].
Subsequently, deficit of intramitochondrial acetyl-CoA
would inhibit transfer of acetyl units to cytoplasm through
different pathways (Fig. 1). Shortage of acetyl-CoA, in
cytoplasm of cholinergic neurons, may decrease ACh level
in this compartment, through ChAT equilibrium mecha-
nism (Table 1; Fig. 2b, c, d) [66]. That in turn would
reduce vesicular ACh pool available for quantal release. In
this manner overload of postsynaptic cholinergic neurons
with Zn could cause immediate depression of ACh syn-
thesis, as well as its vesicular accumulation and release at
early steps of neurodegeneration [46]. On the other hand,
chronic excess of Zn could result in either death of some
cholinergic neurons or depression ChAT activity in those
surviving in these pathogenic conditions [37, 38]. Our
studies revealed that differentiated cholinergic neuronal
cells SN56, with high expression of the cholinergic phe-
notype, were more susceptible to Zn as well as other
neurotoxic signals than those with low level of cholinergic
metabolism (Table 1) [27, 38, 131]. This differential,
phenotype-dependent susceptibility of septal cholinergic
neurons to Zn-induced inputs could be directly linked with
insufficient availability of acetyl-CoA in the mitochondrial
compartment (Fig. 2a, b) [37, 38].
Zn itself may also increase Ca accumulation in the
neurons, thereby facilitating opening PTP and release of
cytochome c, caspases and other proapoptotic proteins
from mitochondria [27, 116, 132]. This excess of Ca
accumulated exclusively in the cytoplasmic compartment
of cholinergic neuronal cells in Zn concentration-depen-
dent pattern [38]. It could trigger PTP formation and
aberrant compartmentalization of acetyl-CoA yielding
cholinergic neurons injuries [37, 118, 124, 130].
NO Excess
Gutamate-Zn evoked increase of [Ca2?]/[calmodulin-Ca]
in cytoplasmic compartments of postsynaptic neurons and
adjacent glial cells markedly increases nNOS and eNOS
activities, respectively [113, 117]. It seems however, that
only increased expression of Ca-independent iNOS in the
microglial/astroglial cells may contribute significantly to
neurodegeneration. It has been demonstrated, that only
iNOS-dependent activation may elevate the NO levels in
the brain up to low micromolar, pathologically relevant,
concentrations [113]. In fact, bacterial lipopolysaccharides
could induce several-fold increase of NO synthesis by
microglia [133]. On the other hand, fraction of NO pro-
duced by nNOS/eNOS may reach levels two orders of
magnitude lower, and is likely to play a physiologic roles
of ‘‘volume transmitter’’ and guanyl cyclase activator
[117].
Peroxynitrite radicals were found to react with wide
range of intracellular biomolecules linked with energy
metabolism, glycolytic metabolism and several regulatory
and transport or neurotransmitter functions, as well as with
antioxidant systems. Excess of endogenous NO exerts
rapid but reversible inhibition of cytochrome c oxidase and
less potent one for other proteins of respiratory chain and
ATP-synthetase, as well [113, 117]. However, NO may
also inhibit earlier steps of energy metabolism including:
PDHC, aconitase, isocitrate NADP-dehydrogenase, as well
as KDHC [35, 77, 79]. Other enzymes of TCA cycle:
succinate dehydrogenase, fumarase, and malate dehydro-
genase were not affected by these conditions. That could
cause deficits of acetyl-CoA and ATP in neuronal cells
exposed to NO/ONOO- excess [77, 79] Cholinergic neu-
rons with residual expression of the cholinergic phenotype
appeared to be more resistant to NO neurotoxicity than
those with high expression of the cholinergic phenotype,
apparently due to negligible demand for acetyl-CoA to
support ACh synthesis in the former (Table 1; Fig. 2f) [35,
77, 79].
Lipoic acid or ALC were found to exert positive effects
on viability of NO or Zn treated cholinergic SN56 cells
through preservation of high acetyl-CoA levels in their
subcellular compartments (Fig. 2) [27, 35]. However, delay
in cytoprotectant application markedly diminished their
efficacy, apparently due to instant, irreversible inactivation
of aconitase by Zn and NO excess [27, 37, 38]. ChAT
appeared to be resistant to direct, acute exposition to NO-
excess. However, short exposition of differentiated SN56
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cells to NO excess caused after 24 h delayed adaptative
suppression of ChAT activity, apparently induced by
shortages of acetyl-CoA in their mitochondrial and cyto-
plasmic compartments (Fig. 2b, c, d; Table 1) [15, 27, 77].
Additive effects of NO excess and Ab were also observed
(Table 1) [79]. Finally, alterations in activities of enzymes
of energy metabolism in SNP-treated differentiated SN56
cells displayed pattern, similar to that reported for human
AD brains [13, 35, 79]. Also cholinergic cells derived from
basal forebrain were more sensitive to NO excess that those
originated from brain stem, as indicated by their phospho
ERK-2 and DNA fragmentation levels (Table 1) [134]. NO
excess increased TUNEL reactivity, lactate dehydrogenase
release and the decrease in ChAT activity in primary
cholinergic neurons from medial septum, whereas those
from brain stem were resistant to such conditions (Table 1)
[135–137]. These data indicate that NO-derived radicals
may exert differential cholinergic phenotype-specific neu-
rotoxic effects in the brain.
Amyloid-b Neurotoxicity
Accumulation of fibrillar Ab deposits in the interstitial
compartments of the brain is a hallmark of AD and related
amyloid encephalopathies [98, 99, 138]. The disruption of
the cholinergic system and suppression of oxidative glu-
cose metabolism were observed in brain regions with Ab
burden. Therefore, Ab load was claimed to be the key
factor triggering and supporting progress of the disease [98,
99]. However, degree of cognitive impairment correlated
much better with loss of cholinergic neurons and impair-
ment of oxidative metabolism than with Ab burden in AD
brains [13, 139]. In addition, some cholinergic encepha-
lopathies develop without accumulation of Ab but with
impairment in brain energy metabolism [140–142]. More-
over, AD-type pathologic changes were found to affect
about 80 % of individuals of age 65, but only small frac-
tion of them suffers of dementia [143]. Therefore, Ab
overload in the brain should be treated as diagnostic and
staging biomarker, and not as causative factor for this
pathology [144, 145]. On the other hand, one cannot
exclude possibility that Ab, after reaching some hypo-
thetical critical level, might aggravate preceding neuro-
toxic signals, triggering vicious cycle of
neurodegeneration. For instance, extracellular fibrillar
aggregates of Ab were found to form autonomic or
NMDA-linked high conductance Ca-channels in plasma
membranes triggering Ca-dependent mechanisms of cyto-
toxicity, including depression of energy metabolism [115].
However, effective, cytotoxic concentrations of Ab in
most in vitro experimental conditions appeared to be an
order of magnitude higher than those detected in AD brains
varying from 0.5 to 4.0 lmol/kg [145–147].
Ab1–42 in nontoxic, submicromolar concentrations
inhibited PDHC and ACh synthesis/release in cultured
primary septal neurons, without changing their ChAT
activity [148]. This peptide also inhibited oxidative
metabolism and decreased ATP contents in the PC12 cells
[149]. Short time exposition to high 50 lmol/L Ab inhib-
ited glucose uptake and increased synthesis of free radicals
in brain synaptosomes [150]. Differential, phenotype-
dependent susceptibility of neurons to Ab was reported by
Olesen et al. [151]. They found, that immortalized raphe
nucleus neurons, when differentiated to cholinergic phe-
notype with brain-derived neurotrophic factor became
three times more sensitive to Ab than those differentiated
to serotoninergic phenotype with ciliary neurotrophic fac-
tor (Table 1) [151]. In addition, Ab caused two times
greater increase of free Ca in hippocampal than in cortical
neurons [152]. Also injection of Ab into rat nucleus basalis
induced deficits of cholinergic neurons but increased
activity of serotoninergic ones [153]. In cerebral neurons,
Ab inhibited cytochrome P450 epoxygenase, which
metabolized arachidonic acid to neuroprotective epoxyei-
cosatrienoic acid, being inactive toward its cerebellar iso-
form. Therefore, cerebral and cerebellar neurons appeared
to be prone and resistant to Ab, respectively [154]. Dif-
ferentiation of cultured embryonal rat brain neurons
increased their susceptibility to Ab [155]. It was due to
activation of their cyclin-dependent kinase 5, which pro-
motes tau phosphorylation, responsible for tubulin disin-
tegration in Ab-exposed neurons [155]. There is also
known that energy deficits in different pathologies of aging
brain induce b-processing of APP [94, 156]. On the con-
trary, dietary high energy substrates were found to reverse
neuronal hyperactivity in transgenic AD mice [157].
Studies on differentiated cholinergic SN56 cells revealed
that their greater susceptibility to Ab could be caused by
lower activity of PDHC, yielding decreased availability of
acetyl-CoA in their mitochondria. In addition, high basal
levels of Ca both in mitochondrial and cytoplasmic com-
partments of differentiated cells, could facilitate detri-
mental effects of Ab (Fig. 2a, e; Table 1) [27, 55, 79]. Also
increased expression of p75 receptors in differentiated cells
could augment their sensitivity to Ab in the presence of
NGF [27, 54, 158]. There are also indications that Ab may
aggravate neurotoxic effects of other AD-linked toxins
such as Al, Zn or peroxinitrine radicals (see ‘‘Zn Neuro-
toxicity’’, ‘‘NO Excess’’) [79, 113, 118, 159]. It has been
found, that Ab, Al or NO excess exerted cumulative sup-
pressive effects on PDHC and aconitase activities, acetyl-
CoA levels, cholinergic metabolism and viability cholin-
ergic SN56 cells in culture (Figs. 1, 2) [27, 79, 118].
On the other hand, regional accumulation of Ab in human
AD brain did not correlate with loss of respective cognitive
functions [139, 160]. Accordingly, in number of patients
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with heavy Ab load, but with normal deposition of amyloid P
in the brain cortex and hippocampus, no signs of dementia
have been found. On the other hand, individuals with mod-
erate Ab accumulation and high content of amyloid P dis-
played typical symptoms of AD dementia [161].
Also in 3xTgAD mice cognitive impairment appeared
before formation any Ab and tau deposits in their brains
[162]. Apparently, Ab accumulation should be considered
rather as an outcome than a trigger of AD neurodegener-
ation [145, 163]. However, it does not exclude possibility
that accumulated Ab might in combination with earlier
cytotoxic signals aggravate end stages of cholinergic
encephalopathies.
Transgenic Animal Models of Cholinergic Degeneration
Several transgenic mice (Tg) models have been developed
to study mechanisms of Ab-dependent neurodegeneration
and investigate putative therapeutic approaches to AD. All
of Tgs were designed by single or multiple inserts of
mutated APP, PS1 human gen(s) into mice germinal cells.
If the above assumptions are correct, then Tg-AD mice
should display: (1) Ab accumulation in sensitive areas of
the brain cortex in their advanced age, (2) functional and
structural disruption of cholinergic neurons paralleling
deficits of cognitive functions, (3) suppression of energy
metabolism preceding alterations, quoted above.
1. There are significant discrepancies concerning accu-
mulation of Ab1–42 in brains of Tg animals. For
instance, in brains of Tg2576 mice, Ab1–42 levels
reported by different authors varied from 0.13 through
0.94 lmol/kg to over 200 times higher concentrations
of 30 lmol/kg of tissue (Table 1) [164–166]. What is
interesting, the degree of cognitive impairment, and
histochemical amyloid plaque densities were similar in
all strains. Also, strikingly wide range of Ab1–42 levels
was reported for post mortem AD human brains [146,
167]. Such wide dispersion of patholologic values
may, presumably result from still existing analytical
problems concerning Ab recovery, matrix effects,
standardization, or specificity and avidity of used
antibodies.
2. There are also significant differences between altera-
tions in cholinergic marker levels in human AD and
mice Tg brains. In human AD brains, significant
decreases in ChAT activities and other cholinergic
markers correlated with loss of cognitive functions
(see ‘‘Alzheimer’s disease’’). On the other hand, no
losses of ChAT activity and VAChT levels were
observed in brains of demented Tg-AD or TS65DN
mice despite evident cognitive deficits [168, 169].
However, decreases in ACh content and release rates
were found in Tg-AD mentally impaired mice, despite
of normal ChAT activity [166, 170].
3. The inhibition of glucose uptake and pyruvate utiliza-
tion in FVB mice took place, which was likely to cause
deficits of acetyl-CoA for energy and ACh production
(Table 1) [171]. However, no suppressions in PDHC,
aconitase, ICDH-NADP and KDHC activities were
found in brains of 17 months Tg 2576 mice (Table 1)
[165] (Szutowicz, Schliebs unpublished). They remain
in contrast with findings in human AD brains, which
revealed significant decreases in activities of all
enzymes listed above [13]. Data presented here
indicate that in Tg mice structural integrity of cholin-
ergic neurons is better preserved than in human AD
brains. Thus, suppression of ACh metabolism and
dependent cognitive functions in Tg-mice is of func-
tional character, resulting from relatively weak inhibi-
tion of glucose and pyruvate metabolism by
accumulating Ab, which is not deadly to cholinergic
neurons [14, 171, 172].
Thiamine Deficiency Encephalopathy
Animals and humans have no capacity of thiamine ring
synthesis, which is the precursor of thiamine diphosphate
(TDP). TDP is a cofactor of two key enzymes of energy
metabolism PDHC and KDHC, providing acetyl-CoA for
and limiting metabolic flux through TCA cycle, respec-
tively. Therefore, thiamine deficits (TD) impair functions
of all body tissues, yielding multi symptomatic and diverse
clinical presentations of cholinergic transmission deficits.
There are claims that, TD-induced inhibition of oxidative
metabolism might facilitate and exacerbate amyolid plaque
pathology [156, 173, 174]. In consequence, alcohol abuse,
which is a most common worldwide cause of TD, should
be considered as a risk factor for AD [175].
Energy and Acetyl-CoA Metabolism in Thiamine Deficient
Brain
Early studies on pyrithiamine-TD rat brains reported either
no change or slight decrease of acetyl-CoA levels [48, 176].
They however, addressed neither intercellular nor intracel-
lular compartmentalization of this metabolite. So far, only
few studies provided quantitative data on mitochondrial and
cytoplasmic pools of acetyl-CoA in different cellular com-
partments in TD (Table 1, Figs. 1, 2) [36, 131].
In TD brains two major mechanisms seem to contribute to an
early dysfunction and late loss of cholinergic neurons. They
include: primary limitation of acetyl-CoA provision by
unproductive TD-PDHC and secondary excitotoxic over-acti-
vation by glutamate-Zn released from energy-depleted
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glutamatergic neurons [37, 122]. The combination of TD-
evoked, direct inhibition of PDHC and KDHC and Zn-induced
excitotoxicity may aggravate acetyl-CoA and energy shortages
in these conditions [36, 38, 128, 177]. In such conditions
reductions in intramitochondrial levels of acetyl-CoA corre-
lated with loses of cholinergic markers and viability of cho-
linergic neuronal cells (Fig. 2a, b, d) [15, 27, 36–38, 131].
There is well established, that the decrease of cyto-
plasmic acetyl-CoA in TD SN56 cells and brain nerve
terminals resulted from limited availability of this metab-
olite in the mitochondrial compartment (Figs. 1, 2b, c). In
consequence, lower rates of ACh release in TD neurons
positively correlated with decreased concentration of
acetyl-CoA in their cytoplasmic compartment (Fig. 2d)
[38, 131]. These findings fit to a general rule that the rate of
ACh synthesis/release depends on the availability of
acetyl-CoA in cytoplasmic/synaptoplasmic compartment of
cholinergic neurons, irrespective of neurotoxic signal
(Figs. 1, 2c, d) [6, 27, 118]. However, unlike for AD or
other neurotoxic conditions, acute TD altered ChAT
activity neither in pyrithiamine-rat brain synaptosomes nor
in amprolium-SN56 cells [38, 131, 176, 178]. These data
indicate that, at least in early stages of TD, the structure of
cholinergic neurons remained well preserved.
Also in this model of cholinergic pathology, neurons
with high expression of the cholinergic phenotype
appeared to be more susceptible to TD than those with
residual cholinergic activity. There was in line with lower
levels of mitochondrial acetyl-CoA in the DC (Fig. 2c;
Table 1) [131]. Residual ACh metabolism in nondifferen-
tiated cholinergic neurons was not affected by TD-induced
shortages in mitochondrial and cytoplasmic acetyl-CoA
(Table 1, Figs. 1, 2c, d, e) [130]. Other, in vivo observa-
tions on differential regional susceptibility of brain cho-
linergic neurons and energy metabolism to TD remain in
accord with cell culture studies [1, 156, 179].
Choline
Choline is another precursor of ACh, which is utilized in
equivalent amounts with acetyl-CoA for the transmitter
synthesis. Mammalian brain has limited capacity to syn-
thesize its own choline. Therefore, this ACh precursor has
to be transported from intravascular compartment across
the blood brain barrier [180, 181]. Cholinergic neuron
axonal terminals possess highest density CHT1 that are
specific functional proteins for their axonal terminals [182,
183]. It has been suggested, that only choline transported
by CHT1 is available for ACh synthesis.
In pathological conditions, prolonged depolarization of
cholinergic terminals may inhibit CHT1-dependent trans-
port of choline from extracellular space due to collapse of
membrane potential. In such conditions, choline may
originate from hydrolysis of structural membrane phos-
pholipids by phospholipase D [181]. This choline pool
could supplement ACh synthesis and maintain stable
transmitter level during its excessive release in course of
sustained depolarization of cholinergic neurons. However,
if such conditions persist the phosphatidylcholine content
in membranes of cholinergic neurons would decrease,
resulting in their shrinkage and death [181]. That could
contribute to particular susceptibility of cholinergic neu-
rons to neurodegenerative insults [181]. On the contrary,
the increase of extracellular choline to supraphysiological
concentrations increased both basal and depolarization-
evoked ACh release. It indicates, that choline taken up by
low affinity system could also be used for transmitter
synthesis and release. These observations rationalize use of
choline supplementation as a method improving ACh
metabolism in age–evoked disturbances of cholinergic
system in the brain [184, 185]. Unlike acetyl-CoA, choline
provision for ACh synthesis is not directly dependent on
the energy production. However, correction of acetyl-CoA
and energy deficits in aged rats by ALC supply in drinking
water elevated choline uptake as well as ACh synthesis and
release [85, 182].
On the other hand, choline-deficient diets induced defi-
cits of this precursor both in cell membranes and in the
ACh synthesizing compartment [186]. Lack of membrane
integrity could cause the impairment of energy production
in brain mitochondria, leading to increased vulnerability of
cholinergic neurons to neurodegenerative signals along
with appearance of behavioral deficits [186, 187]. Such
reciprocal interactions between aberrant acetyl-CoA/
energy and choline metabolisms may trigger vicious cycle
of early deterioration of cholinergic neurons under various
neurodegenerative conditions.
Future Directions
Vast number of studies has been performed over the past
three decades on the mechanisms of AD and other cho-
linergic encephalopaties. They employed diverse in vivo,
in vitro models, and clinical studies focused mainly on
disturbances in Ab metabolism. Only small fraction of
them focused on malfunctions of energy metabolism and
their role in onset and progress of AD. The latter reveal
decreases in PDHC and KDHC activities, which depress
acetyl-CoA synthesis and utilization, in regions of brain
cortex affected by this pathology [27, 118]. There is
however a significant time gap between observations on
acute, excitotoxic alterations in energy metabolism and late
structural, irreversible changes in the neuronal network
[188]. Therefore, several questions remain to be answered
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regarding time-course transition mechanisms between
early, apparently reversible stages of inhibition of acetyl-
CoA/energy production and delayed, irreversible phase of
impairment of brain cholinergic system. To address this
problem multiple time and neurotoxin dose-dependent
studies on expression and postranlational modifications in
enzymes/proteins of energy metabolism and intracellular
signal transduction pathways should be executed. Further
studies are also necessary on reciprocal, differential acute
and chronic effects of AD pathology on energy/acetyl-CoA
metabolism in dominating class of glutamatergic neurons
as well as astro and microglial cells to link them with acute
and prolonged abberations in their functions and integrity.
They should provide a detailed map of regional and inter/
intracellular compatrmentalization of acetyl-CoA in the
brain. This might pave the path for studies on interventions
aiming to preserve acetyl group metabolism, in manner
adequate to early and late stages of neurodegeneration.
Acknowledgments Work was supported by MNiSW projects 2011
046071 and NN401 0299 37 and GUMed fund St-57.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Butterworth RF, Giguere JF, Besnard AM (1985) Activities of
thiamine-dependent enzymes in two experimental models of
thiamine-deficiency encephalopathy: 1. The pyruvate dehydro-
genase complex. Neurochem Res 10:1417–1428
2. Szutowicz A, Ste˛pien´ M, Bielarczyk H, Kabata J, Łysiak W
(1982) ATP citrate lyase in cholinergic nerve endings. Neuro-
chem Res 7:799–810
3. Szutowicz A, Łysiak W (1980) Regional and subcellular dis-
tribution of ATP-citrate lyase and other enzymes of acetyl-CoA
metabolism in rat brain. J Neurochem 35:775–785
4. Duelli R, Kuschinsky W (2001) Brain glucose transporters:
relationship to local energy demand. News Physiol Sci 16:71–76
5. Roberts EL Jr (2007) The support of energy metabolism in the
central nervous system with substrates other than glucose. In:
Lajtha A, Gibson GE, Dienel GA (eds) Handbook of neuro-
chemistry and molecular neurobiology. Brain energetics. Inte-
gration of molecular and cellular processes. Springer, Berlin,
pp 139–179
6. Szutowicz A, Tomaszewicz M, Bielarczyk H (1996) Distur-
bances of acetyl-CoA, energy and acetylcholine metabolism in
some encephalopathies. Acta Neurobiol Exp 56:323–339
7. Szutowicz A, Tomaszewicz M, Jankowska A, Kisielevski Y
(1994) Acetylcholine synthesis in nerve terminals of diabetic
rats. NeuroReport 5:2421–2424
8. Serres S, Raffard G, Franconi JM, Merle M (2008) Close cou-
pling between astrocytic and neuronal metabolomics to fulfill
anaplerotic and energy needs in the rat brain. J Cereb Blood
Flow Metab 28:712–724
9. Halestrap AP, Wilson MC (2012) The monocarboxylate trans-
porter family—role and regulation. IUBMB Life 64:109–119
10. Wohnsland S, Burgers HF, Kuschinsky W, Maurer MH (2010)
Neurons and neuronal stem cells survive in glucose-free lactate
and in high glucose cell culture medium during normoxia and
anoxia. Neurochem Res 35:1635–1642
11. Dienel GA (2011) Brain lactate metabolism: the discoveries and
the controversies. J Cereb Blood Flow Metab 32:1107–1138
12. Baslow MH (2007) N-acetylaspartate and N-acetylaspartylglu-
tamate. In: Oja SS, Schousboe A, Saransaari P (eds) Handbook of
neurochemistry and molecular biology. Amino acids and peptides
in the nervous system, 3rd edn. Springer, New York, pp 305–346
13. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE (2005)
Mitochondrial abnormalities in Alzheimer brain: mechanistic
implications. Ann Neurol 57:695–703
14. Szutowicz A, Tomaszewicz M, Bielarczyk H, Jankowska A
(1998) Putative significance of shifts in acetyl-CoA compart-
mentalization in nerve terminals for disturbances of cholinergic
transmission in brain. Devel Neurosci 20:485–492
15. Szutowicz A, Tomaszewicz M, Jankowska A, Madziar B, Bie-
larczyk H (2000) Acetyl-CoA metabolism in cholinergic neu-
rons and their susceptibility to neurotoxic inputs. Met Brain Dis
15:29–44
16. Bhatt DP, Houdek HM, Watt JA, Rosenberger TA (2013)
Acetate supplementation increases brain phosphocreatine and
reduces AMP levels with no effects on mitochondrial biogene-
sis. Neurochem Int 62:296–305
17. Soliman ML, Ping KL, Combs CK, Rosenberger TA (2012)
Acetate reduces microglia inflammatory signaling in vitro.
J Neurochem 123:555–567
18. Deelchand DK, Nelson C, Shestov AA, Ugurbil K, Henry PG
(2009) Simultaneous measurement of neuronal and glial metab-
olism in rat brain in vivo using co-infusion of [1,6–13C]glucose
and [1,2,-13C]acetate. J Magn Reson 196:157–163
19. Laughton JD, Bittar P, Charnay Y, Pellerin L, Kovari E, Mag-
istretti PJ, Bouras C (2007) Metabolic compartmentalization in
the human cortex and hippocampus: evidence for a cell- and
region-specific localization of lactate dehydrogenase 5 and
pyruvate dehydrogenase. BMC Neurosci 8:35
20. Halim ND, McFate T, Mohyeldin A, Okagaki P, Korotchkina
LG, Patel MS, Jeoung NH, Harris RA, Schell MJ, Verma A
(2010) Phosphorylation status of pyruvate dehydrogenase dis-
tinguishes metabolic phenotypes of cultured rat brain astrocytes
and neurons. Glia 58:1168–1176
21. Gandhi GK, Cruz NF, Ball KK, Dienel GA (2009) Astrocytes
are poised for lactate trafficking and release from activated brain
and for supply of glucose to neurons. J Neurochem 111:522–536
22. Pellerin L (2003) Lactate as a pivotal element in neuron-glia
metabolite cooperation. Neurochem Int 43:331–338
23. Bergersen LH (2007) Is lactate food for neurons? Comparison of
monocarboxylate transporter subtypes in brain and muscle.
Neuroscience 145:11–19
24. Sonnewald U, Schousboe A, Qu H, Waagepetersen HS (2004)
Intracellular metabolic compartmentation assessed by 13C
magnetic resonance spectroscopy. Neurochem Int 45:305–310
25. Leong SF, Lai JCK, Lim L, Clark JB (1981) Energy-metabol-
ising enzymes in brain regions of adult and aging rats. J Neu-
rochem 37:1548–1556
26. Szutowicz A, Jankowska A, Blusztajn JK, Tomaszewicz M
(1999) Acetylcholine and acetyl-CoA metabolism in differenti-
ating SN56 septal cell line. J Neurosci Res 57:131–136
27. Szutowicz A, Bielarczyk H, Gul S, Ronowska A, Pawełczyk T,
Jankowska-Kulawy A (2006) Phenotype-dependent susceptibil-
ity of cholinergic neuroblastoma cells to neurotoxic inputs.
Metab Brain Dis 21:149–161
28. Cremer JE, Teal HM (1974) The activity of pyruvate dehedro-
genase in rat brain during postnatal development. FEBS Lett
39:17–20
Neurochem Res (2013) 38:1523–1542 1537
123
29. Malloch GDA, Munday LA, Olson MS, Clark JB (1986)
Comparative development of the pyruvate dehydrogenase
complex and citrate synthase in rat brain mitochondria. Biochem
J 238:729–736
30. Buerstatte CR, Behar KL, Novotny EJ Jr, Lai JCK (2000)
Brain regional development of the activity and a-ketoglutarate
dehydrogenase complex in the rat. Devel Brain Res 125:
139–145
31. Szutowicz A, Kabata J, Łysiak W (1980) ATP citrate lyase and
other enzymes of acetyl-CoA metabolism in developing rat
cerebrum and cerebellum. Int J Biochem 11:545–549
32. Albers DS, Beal MF (2000) Mitochondrial dysfunction and
oxidative stress in aging and neurodegenerative disease. J Neu-
ral Transm [Suppl] 59:133–154
33. Di Domenico F, Perluigi M, Butterfield DA, Cornelius C,
Calabrese V (2010) Oxidative damage in rat brain during aging:
interplay between energy and metabolic key target proteins.
Neurochem Res 35:2184–2192
34. Uranga RM, Bruce-Keller AJ, Morrison CD, Fernandez-Kim
SO, Ebenezer PJ, Zang L, Dasuri K, Keller JN (2010) Inter-
section between metabolic dysfunction, high fat diet consump-
tion and brain aging. J Neurochem 114:344–361
35. Bielarczyk H, Gul S, Ronowska A, Bizon-Zygman´ska D,
Pawełczyk T, Szutowicz A (2006) RS-a-lipoic amid protects
cholinergic cells against sodium nitroprusside and amyloid-b
neurotoxicity through restoration of acetyl-CoA level. J Neuro-
chem 98:1242–1251
36. Jankowska-Kulawy A, Bielarczyk H, Pawełczyk T, Wro´blewska
M, Szutowicz A (2010) Acetyl-CoA and acetylcholine metab-
olism in nerve terminal compartment of thiamine deficient rat
brain. J Neurochem 115:333–342
37. Ronowska A, Gul-Hinc S, Bielarczyk H, Pawełczyk T, Szuto-
wicz A (2007) Effects of zinc on SN56 cholinergic neuroblas-
toma cells. J Neurochem 103:972–983
38. Ronowska A, Dys´ A, Jankowska-Kulawy A, Klimaszewska-
Łata J, Bielarczyk H, Romianowski P, Pawełczyk T, Szutowicz
A (2010) Short-term effects of zinc on acetylcholine metabolism
and viability of SN56 cholinergic neuroblastom cells. Neuro-
chem Int 56:143–151
39. Paradies G, Pertosillo G, Paradies V, Ruggiero FM (2011)
Mitochondrial dysfunction in brain aging: role of oxidative
stress and cardiolipin. Neurochem Int 58:447–457
40. Zhou Q, Lam PY, Han D, Cadenas E (2009) Activation of c-Jun-
N-terminal kinase and decline of mitochondrial pyruvate dehy-
drogenase activity during brain aging. FEBS Lett 583
:1132–1140
41. Guynn RW, Gelberg HJ, Veech R (1973) Equilibrium constants
of the malate dehydrogenase, citrate synthase, citrate lyase, and
acetyl-CoA hydrolysis reactions under physiological conditions.
J Biol Chem 248:6957–6965
42. Choi CH, Zimon A, Usheva A (2005) Metabolic stress regulates
basic transcription through acetyl-coenzyme A. Cell Mol Life
Sci 62:625–628
43. Ricny J, Tucek S (1980) Relation between the content of acetyl-
coenzyme A and acetylcholine in brain slices. Biochem J
188:683–688
44. Szutowicz A, Łysiak W, Angielski S (1977) Effect of (-)hy-
droxycitrate on pyruvate metabolism in rat brain synaptosomes.
J Neurochem 29:375–378
45. Bielarczyk H, Szutowicz A (1989) Evidence for the regulatory
function of synaptoplasmic acetyl-CoA in acetylcholine syn-
thesis in nerve endings. Biochem J 262:377–380
46. Deutsch J, Rapoport SI, Rosenberger TA (2003) Valproyl-CoA
and estrified valproic acid are not found in brains of rats treated
with valproic acid, but the brain concentrations of CoA and
acetyl-CoA are altered. Neurochem Res 28:861–866
47. Kato T (1978) Ischemic effect on CoASH and acetyl-CoA
concentration levels in cerebrum, cerebellum and liver of mice.
J Neurochem 31:1545–1547
48. Reynolds SF, Blass JP (1975) Normal levels of acetyl coenzyme
A and acetylcholine in the brains of thiamine deficient rats.
J Neurochem 24:185–186
49. Ricny J, Tucek S (1981) Acetyl-coenzyme A and acetylcholine
in slices of rat caudate nuclei incubated in the presence of
metabolic inhibitors. J Biol Chem 256:4919–4923
50. Ricny J, Tucek S (1983) Ca2? ions and the output of acetyl-CoA
from brain mitochondria. Gen Physiol Biophys 2:27–37
51. Shea PA, Aprison MH (1977) The distribution of acetyl-CoA in
specific areas of the CNS of the rat and measured by modifi-
cation od a radio-enzymatic assay for acetylcholine and choline.
J Neurochem 28:51–58
52. Schuberth J, Sollenberg J, Sundwall A, Sorbo B (1966) Acet-
ylcoenzyme A in brain. The effect of centrally active drugs,
insulin coma and hypoxia. J Neurochem 16:819–822
53. Szutowicz A, Bielarczyk H (1987) Elimination of CoA-SH
interference from acetyl-CoA assay by maleic anhydride. Anal
Biochem 164:292–296
54. Szutowicz A, Madziar B, Pawełczyk T, Tomaszewicz M, Bie-
larczyk H (2004) Effect of NGF on acetylcholine, acetyl-CoA
metabolism, and viability of differentiated and non-differenti-
ated cholinergic neuroblastom cells. J Neurochem 90:952–961
55. Szutowicz A, Bielarczyk H, Gul S, Zielin´ski P, Pawełczyk T,
Tomaszewicz M (2005) Nerve growth factor and acetyl-L-car-
nitine evoked shifts in acetyl-CoA and cholinergic SN56 cell
vulnerability to neurotoxic inputs. J Neurosci Res 79:185–192
56. Bielarczyk H, Tomaszewicz M, Szutowicz A (1998) Effect of
aluminium on acetyl-CoA and acetylcholine metabolism in
nerve terminals. J Neurochem 70:1175–1181
57. Srere PA (1965) The molecular physiology of citrate. Nature
205:766–770
58. Tucek S, Dolezal V, Sullivan AC (1981) Inhibition of the syn-
thesis of acetylcholine in rat brain slices by (-)hydroxycitrate
and citrate. J Neurochem 36:1331–1337
59. Dolezal V, Tucek S (1981) Utilization of citrate acetylcarnitine,
acetate and glucose for the synthesis of acetylcholine in rat brain
slices. J Neurochem 36:1323–1330
60. Ricny J, Tucek S, Novakova J (1992) Acetylcarnitine, carnitine
and glucose diminish the effect of muscarinic antagonist qui-
nuclidinyl benzilate on striatal acetylcholine content. Brain Res
576:215–219
61. Scafidi S, Fiskum G, Lindauer SL, Bamford P, Shi D, Hopkins I,
McKenna MC (2010) Metabolism of acetyl-L-carnitine for
energy and neurotransmitter synthesis in the immature brain.
J Neurochem 114:820–831
62. Barsukova A, Komarov A, Hajnoczky G, Bernardi P, Bourdette
D, Forte M (2011) Activation of the mitochondrial permeability
transition pore modulates Ca2? responses to physiological
stimuli in adult neurons. Eur J Neurosci 33:831–842
63. Madhavarao NC, Chinopoulos C, Chandrasekaran K, Namboo-
diri MAA (2003) Characterization of the N-acetylaspartate
biosynthetic enzyme from rat brain. J Neurochem 86:824–835
64. Watanabe T, Shiino A, Akiguchi I (2012) Hippocampal
metabolites and memory performances in patients with amnestic
mild cognitive impairment and Alzheimer’s disease. Neurobiol
Learn Mem 97:289–293
65. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR,
Thompson CB (2009) ATP-citrate lyase links cellular metabo-
lism to histone acetylation. Science 324:1076–1080
66. Tucek S (1993) Short-term control of the synthesis of acetyl-
choline. Prog Biophys Molec Biol 60:59–69
67. Eiden LE (1998) The cholinergic gene locus. J Neurochem
70:2227–2240
1538 Neurochem Res (2013) 38:1523–1542
123
68. Hartikka J, Hefti F (1988) Development of septal cholinergic
neurons in culture: plating density and glial cells modulate
effects of NGF on survival, fiber growth, and expression of
transmitter specific enzymes. J Neurosci 8:2967–2985
69. Auld DS, Mennicken F, Quirion R (2001) Nerve growth factor
rapidly induces prolonged acetylcholine release from cultured
basal forebrain neurons: differentiation between neuromodula-
tory and neurotrophic influences. J Neurosci 21:3375–3382
70. Yamada T, Inazu M, Tajima H, Matsumiya T (2011) Functional
expression of choline transporter-like protein 1 (CTL1) in
human neuroblastom cells and its link to acetylcholine synthesis.
Neurochem Int 58:354–365
71. Efange SMN, Garland EM, Stanley JK, Khare AB, Mash DC
(1997) Vesicular acetylcholine transporter density and Alzhei-
mer’s disease. Neurobiol Aging 18:407–413
72. Schliebs R, Arendt T (2006) The significance of the cholinergic
system in the brain during aging and Alzheimer’s disease.
J Neural Transm 113:1625–1644
73. Vanucchi MG, Pepeu G (1987) Effect of phosphatidylserine on
acetylcholine release and content in cortical slices from aging
rats. Neurobiol Aging 8:403–407
74. Wang F, Chen H, Sun X (2009) Age-related spatial cognitive
impairment is correlated with a decrease in ChAT in cerebral
cortex, hippocampus and forebrain of SAMP8 mice. Neurosci
Lett 454:212–217
75. Fortress AM, Buhusi M, Helke KL, Granholm ACE (2011)
Cholinergic degeneration and alterations in the TrkA and
p75NTR balance as a result of pro-NGF injection into aged rats.
J Aging Res. doi:10.4061/2011/460543
76. Richardson PJ (1981) Quantitation of cholinergic synaptosomes
from guinea pig brain. J Neurochem 37:258–260
77. Bielarczyk H, Tomaszewicz M, Madziar B, C´wikowska J,
Pawełczyk T, Szutowicz A (2003) Relationships between cho-
linergic phenotype and acetyl-CoA level in hybrid Marine neu-
roblastoma cells of sep tal origin. J Neurosci Res 73:717–721
78. Lefresne P, Guyenet P, Glowinski J (1973) Acetylcholine syn-
thesis from [2-14C] pyruvate in rat striatal slices. J Neurochem
20:1083–1097
79. Bielarczyk H, Jankowska A, Madziar B, Matecki A, Michno A,
Szutowicz A (2003) Differential toxicity of nitric oxide, alu-
minum and amyloid-beta peptide in SN56 cholinergic cells from
mouse septum. Neurochem Int 42:323–331
80. Cai L, Sutter BM, Li B, Tu BP (2010) Acetyl-CoA induces cell
growth and proliferation by promoting the acetylation of his-
tones at growth genes. Mol Cell 42:426–437
81. Irwin DJ, Cohen TJ, Grossman M, Arnold SE, Xie SX, Lee
VMY, Trojanowski JQ (2012) Acetylated tau, a novel patho-
logical signature in Alzheimer’s disease and other tauopathies.
Brain 135:807–818
82. Szutowicz A, Srere PA, Allen CN, Crawford IL (1982) Effects of
septal lesions on enzymes of acetyl-CoA metabolism in the cho-
linergic system of the rat hippocampus. J Neurochem 39:458–463
83. Szutowicz A, Morrison MR, Srere PA (1983) The enzymes of
acetyl-CoA metabolism in differentiating cholinergic (S-20) and
noncholinegric (NIE-1150 neuroblastoma cells. J Neurochem
40:1664–1770
84. Selwyn MJ (1987) Holes in mitochondrial inner membranes.
Nature 330:424–425
85. Ando S, Tadenuma T, Tanaka Y, Fukui F, Kobayashi S, Ohashi
Y, Kawabata T (2001) Enhancement of learning capacity and
cholinergic synaptic function by carnitine in aging rats. J Neu-
rosci Res 66:266–271
86. Aureli T, Miccheli A, Ricciolini R, DiCocco ME, Ramacci MT,
Agelucci L, Ghirardi O, Conti F (1990) Aging brain: effect of
acetyl-L-carnitine treatment on rat brain energy and
phospholipid metabolism. A study by 31P and 1H NMR spec-
troscopy. Brain Res 526:108–112
87. Smeland OB, Meisingset TW, Sonnewald U (2012) Dietary
supplementation with acetyl-L-carnitine in seizure treatment
of phenylenetetrazole kindled mice. Neurochem Int 61:
444–454
88. Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JM, McC-
lure RJ (1995) Clinical and neurochemical effects of acetyl-L-
carnitine in Alzheimer’s disease. Neurobiol Aging 16:1–4
89. Crochemore C, Pena-Altamira E, Virgili M, Monti B, Con-
testabile A (2005) Disease-related regressive alterations of
forebrain cholinergic system in SOD1 mutant transgenic mice.
Neurochem Int 46:357–368
90. Fiskum G, Murphy AN, Beal FM (1999) Mitochondria in neu-
rodgeneration: acute ischemia an chronic neurodegenerative
deiseases. J Cereb Bood Flow Metab 19:351–369
91. Martin LJ (2010) Mitochondrial pathobiology in Parkinson’s
disease and amyotrophic lateral sclerosis. J Alzheimer’s Dis
20:S335–S356
92. Pappas BA, Bayley PJ, Bui BK, Hansen LA, Thal LJ (2000)
Choline acetyltransferase activity and cognitive domain scores
of Alzheimer’s patients. Neurobiol Aging 21:11–17
93. Higgins GC, Beart PM, Shin YS, Chen MJ, Cheung NS, Nagley
P (2010) Oxidative stress: emerging mitochondrial and cellular
themes and variations in neuronal injury. J Alzheimer’s Dis
20(Suppl 2):S453–S473
94. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxi-
dative stress in neurodegenerative diseases. Nature 443:787–795
95. Morais VA, De Strooper B (2010) Mitochondrial dysfunction
and neurodegenerative disorders: cause or consequence. J Alz-
heimer’s Dis 20(Suppl 2):S255–S263
96. Sun J, Feng X, Liang D, Duan Y, Lei H (2012) Down-regulation
of energy metabolism in Alzheimer’s disease is a protective
response of neurons to the microenvironment. J Alzheimer’s Dis
28:389–402
97. Hoyer S, Frolich I (2007) Dementia: the significance of cerebral
metabolic disturbances in Alzheimer’s disease. Relation to
Parkinson’s disease. In: Lajtha A, Moussa BH, Riederer P,
Mandel SA, Battistin L (eds) Handbook of neurochemistry and
molecular biology 3rd edition, degenerative diseases of the
nervous system. Springer, New York, pp 189–232
98. Selkoe DJ (1994) Alzheimer’s disease: a central role of amyloid.
J Neuropath Exp Neurol 53:438–449
99. Walsh DM, Selkoe DJ (2007) Ab oligomers—a decade of dis-
covery. J Neurochem 101:1172–1184
100. Xu PT, Li YJ, Qin XJ, Scherzer CR, Xu H, Schmechel DE,
Hulette CM, Ervin J, Gullans SR, Haines J, Peicak-Vance MA,
Gilbert JR (2006) Differences in apolipoprotein E3/3 and E4/E4
allele-specific gene expression in hippocampus in Alzheimer’s
disease. Neurobiol Dis 21:256–275
101. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE
(2007) Systematic meta-analyses of Alzheimer disease genetic
association studies: the AlzGene database. Nature Gen 39:17–23
102. Manji H, Kato T, Di Prospero NA, Ness S, Beal MF, Krams M,
Chen G (2012) Impaired mitochondrial function in psychiatric
disorders. Nature Rev Neurosci 13:293–307
103. Chen HK, Ji YS, Dodson SE, Miranda RD, Rosenblum CI, Rey-
nolds IJ, Freedman SB, Weisgraber KH, Huang Z, Mahlez RW
(2011) Apolipoprotein E4 domain interaction, mediates detri-
mental effects on mitochondria and is a potential therapeutic
target for Alzheimer disease. J Biol Chem 286:5215–5221
104. Gibson GE, Haroutunian V, Zang H, Park LCH, Shi Q, Lesser
M, Mohs RC, Sheu RKF, Blass JP (2000) Mitochondrial damage
in Alzheimer’s disease varies with apolipoprotein E genotype.
Ann Neurol 48:297–303
Neurochem Res (2013) 38:1523–1542 1539
123
105. Terwel D, Bothmer J, Wolf E, Meng F, Jolles J (1998) Affected
enzyme activities in Alzheimer’s disease are sensitive to ante-
mortem hypoxia. J Neurol Sci 161:47–56
106. Benson DF (1983) Alterations in glucose metabolism in Alz-
heimer’s disease. Banbury report 15. Cold Spring Harbor Lab-
oratory, pp 309–315
107. Kalaria RN, Harik SI (1989) Reduced glucose transporter at
blood-brain barrier and in cerebral cortex in Alzheimer’s dis-
ease. J Neurochem 53:1083–1088
108. Bierer LM, Haroutunian V, Gabriel S, Knott PJ, Carlin LS,
Purohit DP, Perl DP, Schmeidler J, Kanof P, Davis KL (1995)
Neurochemical correlates of dementia severity in Alzheimer’s
disease: relative importance of cholinergic deficits. J Neurochem
64:749–760
109. Armstrong DM, Sheffield R, Mishizen-Eberz AJ, Carter TL,
Rissman RA, Mizukami K, Ikonomovic MD (2003) Plasticity of
glutamate and GABAA receptors in the hippocampus of patients
with Alzheimer’s disease. Cell Mol Neurobiol 23:491–505
110. Lyness SA, Zarow C, Chui HC (2003) Neuron loss in key
cholinergic and aminergic nuclei in Alzheimer disease: a meta-
analysis. Neurobiol Aging 24:1–23
111. Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The
cholinergic hypothesis of Alzheimer’s disease: a review of
progress. J Neurol Neurosurg Psychiatry 66:137–147
112. Kar S, Slowikowski S, Westway D, Mount HTJ (2004) Inter-
actions between b-amyloid and central cholinergic neurons:
implications for Alzheimer’s disease. J Psychiatry Neurosci
29:427–441
113. Moncada S, Bolanos JP (2006) Nitric oxide, cell bioenergetics
and neurodegeneration. J Neurochem 97:1676–1689
114. Murphy MP, LeVine H III (2010) Alzheimer’s disease and
amyloid-b peptide. J Alzheimer’s Dis 19:311–323
115. Berridge MJ (2011) Calcium signaling and Alzheimer’s disease.
Neurochem Res 36:1149–1156
116. Sensi SL, Paoletti P, Bush AI, Sekler I (2009) Zinc in the
physiology and pathology of the CNS. Nat Rev Neurosci
10:780–792
117. Steinert JR, Chernova T, Forsythe ID (2010) Nitric oxide sig-
naling in brain function, dysfunction, and dementia. Neurosci-
entist 16:435–452
118. Szutowicz A (2001) Aluminum, NO, and nerve growth factor
neurotoxicity in cholinergic neurons. J Neurosci Res 66:
1009–1018
119. Caricasole A, Copani A, Caruso A, Caraci F, Iacovelli L, Sor-
tino MA, Terstappen GC, Nicoletti F (2003) The Wnt pathway,
cell-cycle activation and b-amyloid: novel therapeutic strategies
in Alzheimer’s disease? Trends Pharmacol Sci 24:233–238
120. Perez SE, He B, Muhmmad N, Oh KJ, Fahnestock M, Iko-
nomovic MD, Mufson EJ (2011) Cholinotropic basal forebrain
system alterationsin 3xTg-AD transgenic mice. Neurobiol Dis
41:338–352
121. Oh JD, Chartisathian K, Chase TN, Butcher LL (2000) Over-
expression of neurotrophin receptor p75 contributes to the ex-
citotoxin-induced cholinergic neuronal death in rat basal
forebrain. Brain Res 853:174–185
122. Takeda A (2011) Zinc signaling in the hippocampus and its relation
to pathogenesis of depression. Mol Neurobiol 44:166–174
123. Frederickson CJ, Maret W, Cuajungco MP (2004) Zinc and
excitotoxic brain injury. Neuroscientist 10:18–25
124. Mocchegiani E, Bertoni-Freddari C, Marcellini F, Malavolta M
(2005) Brain, aging and neurodegeneration: role of zinc ion
availability. Progr Neurobiol 75:367–390
125. Hynd MR, Scott HL, Dodd PR (2004) Glutamate-mediated ex-
citotoxicity and neurodegeneration in Alzheimer’s disease.
Neurochem Int 45:583–595
126. Supnet C, Bezprozvanny I (2010) Neuronal calcium signaling,
mitochondrial dysfunction, and Alzheimer’s disease. J Alzhei-
mer’s Dis 20:S487–S498
127. Yu JT, Chang RCC, Tan L (2009) Calcium dysregulation in
Alzheimer’s disease: from mechanisms to therapeutic opportu-
nities. Progr Neurobiol 89:240–255
128. Jhala SS, Hazell AS (2011) Modeling neurodegenerative disease
pathophysiology in thiamine deficiency: consequences of
impaired oxidative metabolism. Neurochem Int 58:248–260
129. Lai CKJ, DiLorenzo JC, Sheu KFR (1988) Pyruvate dehydro-
genase is inhibited in calcium-loaded cerebrocortical mito-
chondria. Neurochem Res 13:1043–1048
130. Zatta P, Lucchini R, Rensburg SJ, Taylor A (2003) The role of
metals in neurodegenerative process: aluminum, manganese and
zinc. Brain Res Bull 62:15–28
131. Bizon-Zygman´ska D, Jankowska-Kulawy A, Bielarczyk H,
Pawełczyk T, Ronowska A, Marszałł M, Szutowicz A (2011)
Acetyl-CoA metabolism in amprolium-evoked thiamine pyro-
phosphate deficits in cholinergic SN56 neuroblastoma cells.
Neurochem Int 59:208–216
132. Bossy-Wetzel E, Talantova MV, Lee WD, Scholzke MN, Har-
rup A, Mathews E, Gotz T, Han J, Ellisman MH, Perkins GA,
Lipton SA (2004) Crosstalk between nitric oxide and zinc
pathways to neuronal cell death involving mitochondrial dys-
function and p38-activated K? channels. Neuron 41:351–365
133. Doherty GH (2011) Nitric oxide in neurodegeneration: potential
benefits of non-steroidal anti-inflammatories. Neurosci Bull
27:366–382
134. Personett DA, Williams K, Baskerville KA, McKinney M
(2007) Establishment of cholinergic neuron-like cell lines with
differential vulnerability to nitrosative stress. Curr Neurovasc
Res 4:75–88
135. Fass U, Panickar K, Personett D, Bryan D, Williams K, Gonz-
alez J, Sugaya K, McKinney M (2000) Differential vulnerability
of primary cultured cholinergic neurons to nitric oxide excess.
NeuroReport 11:931–936
136. McKinney M, Williams K, Personett D, Kent C, Bryan D,
Gonzalez J, Baskeville K (2004) Pontine cholinergic neurons
depend on three neuroprotection systems to resist nitrosative
stress. Brain Res 1002:100–109
137. Personett D, Fass U, Panickar K, McKinney M (2000) Retinoic
acid-mediated enhancement of the cholinergic/neuronal nitric
oxide synthase phenotype of the medial septal SN56 clone
establishment of nitric oxide-sensitive proapoptotic state.
J Neurochem 74:2412–2424
138. Benilova I, Karran E, De Strooper B (2012) The toxic Ab oli-
gomer and Alzheimer’s disease: an emperor in need of clothes.
Nat Neurosci 15:1–9
139. Furst AJ, Rabinovici GD, Rostomian AH, Steed T, Alkalay A,
Racine C, Miller BL, Jagust WJ (2012) Cognition, glucose
metabolism and amyloid burden in Alzheimer’s disease. Neu-
robiol Aging 33:215–225
140. Butterworth RF (2003) Thiamin deficiency and brain disorders.
Nutr Res Rev 16:277–283
141. Exley C, House ER (2011) Aluminium in the human brain.
Monatsh Chem 142:357–363
142. Zahr NM, Kimberley L, Harper K, Harper CG (2011) Clinical
and pathological features of alcohol-related brain damage.
Nature Rev Neurol 7:284–294
143. Ferrer I (2012) Defining Alzheimer as a common age-related
neurodegenerative process not inevitably leading to dementia.
Progr Neurobiol 97:38–51
144. Klunk WE (2011) Amyloid imaging as a biomarker for cerebral
b-amyloidosis and risk prediction for Alzheimer dementia.
Neurobiol Aging 32:S20–S36
1540 Neurochem Res (2013) 38:1523–1542
123
145. Robakis NK (2011) Mechanisms of AD neurodegeneration may
be independent of Ab and its derivatives. Neurobiol Aging
32:372–379
146. Ishii K, Tamaoka A, Mizusawa H, Shoji SI, Ohtake T, Fraser
PE, Takahashi H, Tsui S, Gearing M, Mizutami T, Yamada S
et al (1997) Ab1-40 but not Ab1-42 levels in cortex correlate
with apolipoprotein E e4 allele dosage in sporadic Alzheimer’s
disease. Brain Res 748:250–252
147. Naslund J, Haroutunian V, Mohs R, Davis KI, Greengard P,
Buxbaum JD (2000) Correlation between elevated levels of
amyloid b-peptide in the brain and cognitive decline. JAMA
283:1571–1577
148. Hoshi M, Takashima A, Yasutake K, Yoshida N, Ishiguro K,
Hoshino T, Imahori K (1997) Nontoxic amyloid b peptide 1–42
suppresses acetylcholine synthesis. J Biol Chem 272:2038–2041
149. Perreira C, Santos MS, Oliveira C (1999) Involvement of oxi-
dative stress on the impairment of energy metabolism induced
by Ab peptides on PC12 cells: protection by antioxidants.
Neurobiol Dis 6:209–219
150. Keller JN, Pang Z, Geddes JW, Germeyer A, Waeg G, Mattson
MPJ (1997) Impairment of glucose and glutamate transport and
induction mitochondrial oxidative stress and dysfunction in
synaptosomes by amyloid-beta peptide: role of the lipid perox-
idation product 4-hydroxynonenal. J Neurochem 69:273–289
151. Olesen OF, Dago L, Mikkelsen JD (1998) Amyloid b neuro-
toxicity in the cholinergic but not in the serotoninergic pheno-
type of RN46A cells. Mol Brain Res 57:266–274
152. Resende R, Pereira C, Agostinho P, Vieira AP, Malva JO,
Oliveira CR (2007) Susceptibility of hippocampal neurons to Ab
peptide toxicity is associated with perturbation in Ca2?
homeostasis. Brain Res 1143:11–21
153. Harkany TO, Mahony S, Keikser J, Kelly JP, Konya C, Boro-
styankoi ZA, Gorcs TJ, Zarandi M, Penke B, Leonard BE, Lu-
iten PGM (2001) b-Amyloid (1–42)-induced cholinergic lesions
in rat nucleus basalis bidirectionally modulate serotonergic
innervation of the basal forebrain and cerebral cortex. Neurobiol
Dis 8:578–667
154. Sarkar P, Narayanan J, Harder DR (2011) Differential effect of
amyloid beta on the cytochrome P450 epoxygenase activity in
rat brain. Neuroscience 194:241–249
155. Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA,
Atwood CS (2004) Amyloid-b-induced toxicity of primary
neurons is dependent upon differentiation-associated increases
in tau and cyclin-dependent kinase 5 expression. J Neurochem
88:554–563
156. Karuppagounder SS, Xu H, Shi Q, Chen LH, Pedrini S, Pech-
man D, Baker H, Beal MF, Gandy S, Gibson GE (2009) Thia-
mine deficiency induces oxidative stress and exacerbates the
plaque pathology in Alzheimer’s mouse model. Neurobiol
Aging 30:1578–1600
157. Zilberter M, Ivanov A, Ziyatdinova S, Mukhatarov M, Malkov
A, ALpar A, Tortoriello G, Botting CH, Fulop L, Osypov AA,
Pitkanen A, Tanila H, Harkany T, Zilberter Y (2013) Dietary
energy substrates reverse early neuronal hyperactivity in a
mouse model of Alzheimer’s disease. J Neurochem. doi:
10.1111/jnc.12127
158. Zeng F, Lu JJ, Zhou XF, Wang YJ (2011) Roles of p75NTR in
the pathogenesis of Alzheimer’s disease: a novel therapeutic
target. Biochem Pharmacol 82:1500–1509
159. Walton JR (2009) Brain lesions comprised of aluminum-reach
cells that lack microtubules may be associated with cognitive
deficit of Alzheimer’s disease. NeuroToxicology 30:
1059–1069
160. Kantarci K, Lowe V, Przybelski SA, Senjem MI, Weingand SD,
Ivnik RJ, Roberts R, Geda YE, Boeve BF, Knopman DS, Pet-
ersen RC, Jack CR Jr (2011) Magentic resonance spectroscopy,
b-amyloid load, and cognition in a population-based sample of
cognitively normal older adults. Neurology 77:951–958
161. Crawford JR, Bjorklund NL, Tagliatella G, Gomer RH (2012)
Brain serum amyloid P levels are reduced in individuals that
lack dementia while having Alzheimer’s disease neuropathol-
ogy. Neurochem Res 37:795–801
162. Blanchard J, Wanka L, Tung YC, Cardenas-Aguayo MC,
LaFerla FM, Iqbal K, Grundke-Iqbal I (2010) Pharmacologic
reversal of neurogenic and neuroplastic abnormalities and cog-
nitive impairments without affecting Ab and tau pathologies in
3xTg-AD mice. Acta Neuropathol 120:605–621
163. Hamilton LK, Aumont A, Julien C, Vadnais A, Calon F,
Fernandes KJL (2010) Widespread deficits in adult neurogenesis
precede plaque and tangle formation in the 3xTg mouse model
of Alzheimer’s disease. Eur J Neurosci 32:905–920
164. Chapman PE, White GL, Jones MW, Cooper-Blacketer D,
Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TVP,
Hyman BT, Younkin SG, Hsiao KK (1999) Impaired synaptic
plasticity and learning in aged amyloid precursor protein
transgenic mice. Nat Neurosci 2:271–276
165. Plaschke K, Kopitz J, Siegelin M, Schliebs R (2010) Insulin-
resistant brain state after intracerebroventricular dtreptozotocin
injection exacerbates Alzheimer-like changes in Tg 2576 AbPP-
overexpressing mice. J Alzheimer’s Dis 19:691–704
166. Watanabe T, Yamagata N, Takasaki K, Sano K, Hayakawa K,
Katsurabayashi S, Egashira N, Mishima K, Iwasaki K, Fujiwara
M (2009) Decreased acetylcholine release is correlated to
memory impairment in the Tg2576 transgenic mouse model of
Alzheimer’s disease. Brain Res 1249:222–228
167. Hellstrom-Lindahl E, Viitanen M, Marutle A (2009) Compari-
son of Ab levels in the brain of familial and sporadic Alzhei-
mer’s disease. Neurochem Int 55:243–252
168. Liu L, Ikonen S, Heikkinen T, Tapiola T, VanGroen T, Tanila H
(2002) The effects of long-term treatment with metrifonate,
cholinesterase inhibitor, on cholinergic activity, amyloid
pathology, and cognitive function in APP and PS1 doubly
transgenic mice. Exp Neurol 173:196–204
169. Contestabile A, Fila T, Bartesaghi R, Contestabile A, Ciani E
(2006) Choline acetyltransferase activity in brain of Ts65Dn
mice, an animal model for Down’s syndrome and related neu-
rodegenerative diseases. J Neurochem 97:515–526
170. Ikarashi Y, Hatigaya Y, Tomidokoro Y, Kanai M, Ikeda M,
Matsubara E, Kawarabayashi T, Kuribara M, Younkin SG,
Maruyama Y, Shoi M (2004) Decreased level of brain acetyl-
choline and memory disturbance in APPsw mice. Neurobiol
Aging 25:483–490
171. Hsiao KK, Borchet DR, Olson K, Johannsdottir R, Kitt C, Yunis
W, Xu S, Eckman C, Younkin S, Price D et al (1995) Age-
related CNS disorder and early death in transgenic FVB/N mice
overexpressing Alzheimer amyloid precursor proteins. Neuron
15:1203–1218
172. Machova E, Rudajev V, Snyckova H, Koivisto H, Tanila H,
Dolezal V (2010) Functional cholinergic damage develops with
amyloid accumulation in young adult APPswe/PS1dE9 trans-
genic mice. Neurobiol Dis 38:27–35
173. Gold M, Hauser RA, Chen MF (1998) Plasma thiamine defi-
ciency associated with Alzheimer’s disease but not Parkinson’s
disease. Met Brain Dis 13:43–53
174. Zhang Q, Yang G, Li W, Fa Z, Sun A, Luo J, Ke ZJ (2011)
Thiamine deficiency increases b-secretase activity and accu-
mulation of b-amyloid peptides. Neurobiol Aging 32:42–53
175. Humpel C (2011) Chronic mild cerebrovascular dysfunction as a
cause for Alzheimer’s disease? Exp Gerontol 46:225–232
176. Heinrich CP, Stadler H, Weiser H (1973) The effect of thiamine
deficiency on the acetylcoenzyme A and acetylcholine levels in
the rat brain. J Neurochem 21:1273–1281
Neurochem Res (2013) 38:1523–1542 1541
123
177. Bubber P, Zj Ke, Gibson GE (2004) Tricarboxylic acid cycle
enzymes following thiamine deficiency. Neurochem Int 45:
1021–1028
178. Zhao N, Zhong C, Wang Y, Zhao Y, Gong N, Zhou G, Xu T,
Hong Z (2008) Impaired hippocampal neurogenesis is involved
in cognitive dysfunction induced by thiamine deficiency at early
pre-pathological lesion stage. Neurobiol Dis 29:176–185
179. Plaitakis A, Hwang EC, Van Woert MH, Szilagyi PI, Berl S
(1982) Effect of thiamin deficiency on brain neurotransmitter
systems. Ann NY Acad Sci 378:367–381
180. Allen DD, Smith QR (1999) Blood-brain barrier choline trans-
port in the senescent rat. Neurosci Lett 277:198–202
181. Wurtman RJ (1992) Choline metabolism as a basis for selective
vulnerability of cholinergic neurons. TINS 15:117–122
182. Yamamura HI, Snyder SH (1973) High affinity transport of
choline into synaptosomes of rat brain. J Neurochem 21:
1355–1374
183. Brock M, Nickel AC, Madziar B, Blusztajn JK, Berse B (2007)
Differential regulation of the high affinity choline transporter
and cholinergic locus by cAMP signaling pathways. Brain Res
1145:1–10
184. Blusztajn JK (1998) Choline, a vital amine. Science 281:
794–795
185. Glenn MJ, Kirby ED, Gibson EM, Wong-Goodrich SJ, Mellot
TJ, Blusztajn JK, Williams CL (2008) Age-related declines in
exploratory behavior and markers of hippocampal plasticity are
attenuated by prenatal choline supplementation in rats. Brain
Res 1237:110–123
186. Liapi C, Kyriakaki A, Zarros A, Al-Humadi H, Stolakis V,
Gkrouzman E, Anifantaki F, Skandali N, Margaritis M, Tsakiris
S (2009) Effect of adult-onset choline deprivation on the
activities of acetylcholinesterase (Na?, K?)- and Mg2?ATPase
in crucial rat brain regions. Food Chem Toxicol 47:82
187. Pacelli C, Coluccia A, Grattagliano I, Cocco T, Petrosillo G,
Paradies G, De Nitto E, Massaro A, Persichella M, Borraci P,
Portincasa P, Carratu MR (2010) Dietary choline deprivation
impairs rat brain mitochondrial function and behavioral pheno-
type. J Nutr 40:1072–1079
188. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD
(2009) Mitochondrial bioenergetic deficit precedes Alzheimer’s
pathology in female mouse model of Alzheimer’s disease. Proc
Natl Acad Sci USA 106:14670–14675
1542 Neurochem Res (2013) 38:1523–1542
123
